Plan B · Case Example · Consented & de-identified
An infection-driven case — with an immune floor and a methylation ceiling.
The data to solve it largely already existed. It had never been read together.
The picture when they came
A teenager with a long history of chronic infection that wouldn’t clear, a previous workup that had landed on “gut and inflammation,” and a parent who had been told the obvious next step (immune-replacement therapy) was an out-of-pocket cost the family couldn’t carry. Multiple antibiotic rotations across multiple practitioners had not moved the needle. The family had a thick folder of testing from several specialty labs — but no one had integrated it into a single picture.
That last part is the whole point of a case like this: the data to solve it largely already existed. It had never been read together.
What the data actually showed
The findings below are described by direction (high / low / low-normal) rather than exact values — the clinical meaning is what matters here.
- Specialty tick-borne microscopy (roughly a year and a half ago) visualized several tick-borne pathogens at once — a multi-pathogen tick-borne picture.
- Confirmatory tick-borne antibody testing showed positive bands.
- An immune marker associated with chronic tick-borne infection came back HIGH — a recognized chronic-Lyme immune signature.
- Historical viral testing documented a chronic enteroviral infection.
- Current bloodwork was consistent with this picture: low iron stores and a low neutrophil count.
From recent hospital bloodwork:
- Two of the main immunoglobulin classes came back LOW, with a third in the low-normal range.
- Total protein was normal but with a low globulin fraction.
- The neutrophil count was LOW — neutropenia flagged by the lab.
- Earlier specialty immune testing had shown low class-switched memory B cells.
Taken together — low immunoglobulins, low class-switched memory B cells, and neutropenia — this is a CVID-spectrum (Common Variable Immunodeficiency–spectrum) picture. That matters enormously, because it is recognized, treatable medicine — not a fringe diagnosis — and the immune-replacement therapy it qualifies for is covered under a national health system through the immunodeficiency indication, which the family had not realized.
From a full SNP panel plus serum testing:
- Serum B12 was HIGH — well above the top of the reference range.
- A methylation-related genotype came back homozygous “slow.”
That combination — a slow methylation genotype plus serum B12 pooling well above the upper limit — is the classic fingerprint of a functional B12 deficiency: the vitamin is in the blood, but the body can’t put it to work. This is the “cleanup engine is genetically slow” finding that explains why aggressive protocols backfired.
Layered on top, the SNP panel pointed to several other inherited bottlenecks in the same cleanup-and-detox machinery:
- Slow catechol clearance — affecting dopamine and histamine handling.
- A compromised antioxidant / glutathione detox pathway.
- A mitochondrial-support deficit.
- A serotonin-pathway genotype associated with higher OCD risk.
- A Vitamin D pathway genetically compromised at multiple steps, predicting functional insufficiency regardless of intake — and notably, no current Vitamin D level was on file at all.
- Reassuringly, the most common high-impact methylation variant (MTHFR C677T) was not present — no C677T burden.
Iron + gut + neuroinflammation
- Iron stores (ferritin) were LOW; the lab itself noted this as consistent with iron deficiency. With the tick-borne picture, this reads as iron deficiency plus an iron-sequestration pattern. (Clinically important: this argues against IV iron, which can feed the infection.)
- A stool/microbiome panel (over a year ago) showed severe dysbiosis — very low diversity, near-absent beneficial species, an overgrowth pattern, elevated histamine-producing bacteria, an elevated bacterial neurotoxin, and a borderline leaky-gut marker.
- Two separate panels six months apart showed the same kynurenine-pathway shift — tryptophan being diverted away from serotonin toward a neurotoxic metabolite — a consistent chronic-neuroinflammation signal.
What was ruled OUT — the good news
- Autoimmune encephalitis — a specialist neuro-autoantibody panel was all negative.
- PANDAS-strep — strep antibody essentially nil; the driver is not strep.
- Mold / mycotoxins — panel negative.
- Folate-receptor antibody — negative.
So this is an infection-driven case with an immune-deficiency floor and a methylation ceiling — not an autoimmune or mold case.
How it integrates
This is the part no single specialist had done. Each finding had been seen by someone, but the connections between them are where the answer lives:
- The immune deficiency is the missing key. It explains why a kid can carry multiple pathogens for years and never clear them no matter how many antibiotics are rotated through. Killing harder doesn’t work when the body can’t make the antibodies to finish the job.
- The methylation/detox block explains the second failure mode: when you do start killing pathogens, a body with a slow cleanup engine gets overwhelmed by the die-off (a Herx crisis). That’s why pace has to be slow and why “preloading” the engine comes before any antimicrobial.
- The iron + neutropenia + low ferritin aren’t a separate problem — they’re downstream of the infection (intracellular pathogens sequester iron and stress the marrow), which is why they belong in the same story rather than being treated in isolation.
- The gut dysbiosis, histamine load, and slow histamine-clearance genetics reinforce each other — histamine-producing bugs in a body that clears histamine slowly — and feed the neuroinflammation picture alongside the kynurenine shift and the OCD-risk serotonin genetics.
The order of operations falls out directly
Immune support first, fix the cleanup engine second, kill the infections third — the reverse of what had been tried.
Frameworks drawn on in the integration: Walsh / Yasko / Lynch (methylation and SNP interpretation), Buhner (herbal antimicrobial sequencing), the PANS Consortium 2017 consensus (IVIG/treatment-response context), O’Hara and Stewart (PANS / neuro-immune lens), Crista (pediatric pathogen/inhalation adjuncts), and the broader chronic-tick-borne literature.
What to ask & test next
These are the questions to bring to a practitioner — framed as “what to investigate,” not “what to do.”
First and most important — the immune workup
Ask a pediatric immunologist to complete a standard CVID workup:
- IgG subclasses 1–4 (the total IgG is low-normal, but the subclasses tell the diagnostic story)
- Pneumococcal antibody titers before and after a booster vaccine (the gold-standard test for Specific Antibody Deficiency — does the immune system respond, not just what’s on hand)
- A genetic primary-immunodeficiency panel (looks for a monogenic cause; matters for family screening and treatment choice)
If this confirms a CVID-spectrum diagnosis, immune-replacement therapy (IVIG or SCIG) is covered under a national health system through the immunodeficiency indication — an avenue the family hadn’t known was open to them, and the single highest-leverage move in the case.
Confirm the methylation block with numbers, not just genetics
- MMA + RBC folate + homocysteine + serum B12, drawn together — distinguishes a true functional B12 deficiency (treat with the active form) from simple over-supplementation, and unmasks tissue folate deficiency that serum folate can hide.
Fill the obvious gaps
- A current 25-OH Vitamin D level — the entire Vitamin D genetic pathway is compromised and there is no number on file to dose from.
- A histamine panel (plasma histamine + tryptase + 24-hr urinary methylhistamine) to settle how much of the symptom picture is histamine-driven.
- EBV 4-marker panel + HHV-6 quantitative PCR to check for smoldering viral reactivation.
- Confirmatory tick-borne serology to give serial markers that can track treatment response (the microscopy result is qualitative).
- Repeat CBC + iron studies at 4–6 weeks, then 12 weeks to watch the neutropenia and ferritin recover as objective response markers.
A note that applies to this whole class of case: do not order the Cunningham Panel as part of the workup, and do not jump to IV iron.
The roadmap, in order
- Immune support first — immunologist referral and CVID workup; immune-replacement therapy if it qualifies.
- Fix the cleanup engine — methylation cofactors (the correct form of B12), glutathione support, iron repletion (oral, gentle form — not IV), Vitamin D once tested. Open drainage before killing.
- Gentle gut restoration — rebuild the beneficial species, calm the histamine load.
- Then the targeted antimicrobial work — gentle herbal-first, sequenced slowly, with the full menu of options available and held in reserve, only once the immune floor is in place.
- Lifelong maintenance — food-first, with ongoing methylation cofactor support, monitored with periodic bloods.
Confidence & caveats
- The immune-deficiency, infection, and methylation findings above are each labeled with the synthesis’s own confidence tags (STRONG / PROVEN / MODERATE / RULED OUT) and none were upgraded for this write-up.
- The recent hospital bloodwork (immunoglobulins, CBC/neutrophils, B12, ferritin) is source-verified against the original lab report. Several of the specialty-lab findings (the SNP panel, the microscopy, the stool panel, the neuro-organic-acid panel) were, at the time of synthesis, transcribed from the prior write-up rather than re-read from the original lab PDFs — so they carry a lower verification bar and were treated as provisional.
- Some findings are older — the class-switched memory B-cell and chronic-Lyme immune-marker results are nearly two years old, and the microscopy and stool panels are over a year old. Old results are flagged for recheck, not treated as the current state.
- This was a draft synthesis pending senior clinical review at the time it was written; treat all conclusions as provisional.
- Plan B is a navigation and integration service, not a medical provider. Everything here is framed as questions to investigate with a qualified practitioner.